《大行报告》野村上调友邦(01299.HK)目标价至81.22元 评级「中性」
野村发表研究报告,指友邦(01299.HK)第二季寿险在香港市场录最差表现,跌幅达50%,主因受疫情影响,来自内地客的首年保费更跌94%,较2017年第四季限制资本外流政策影响更大。
该行指,友邦香港的业务整体首年保费跌71%,离岸业务跌98%,不过目前最差情况已经过去,但仍需静待香港业务的复苏,因目前内地客对多元化的环球投资产品需求仍存,但近期或有所转弱,因人民币贬值情况暂停、中美关系紧张、保费差距收窄,料需至2022年恢复。
该行又指,调整2020-22年新业务价值预期分别-21%、24%、22%,升目标价12%至81.22元,评级维持「中性」。(ic/a) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.